SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 19th, 2007 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 17, 2007, by and among Titan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
CONFIDENTIAL November 28, 2007 Titan Pharmaceuticals, Inc. Suite 505 South San Francisco, California 94080Titan Pharmaceuticals Inc • December 19th, 2007 • Biological products, (no disgnostic substances) • New York
This letter (the “Agreement”) will confirm the basis upon which Titan Pharmaceuticals, Inc. (“Client”) has engaged Canaccord Adams Inc. (together with its affiliates, control persons, officers, directors, employees and agents, “CA”) to act as Client’s lead placement agent and financial advisor, and Rodman & Renshaw, LLC (together with its affiliates, control persons, officers, directors, employees and agents, “Rodman” and together with CA, the “Placement Agents”) to act as co-placement agent and co-financial advisor in connection with a private placement, on a best efforts basis, of one or more classes or series of securities of the Company (the “Securities”). The Securities may take the form of common stock and/or other equity-related securities. The placement of the Securities shall be referred to as the “Private Placement.” CA will act as the representative of the Placement Agents.
